EurekaMag.com logo
+ Translate

Evaluation of a new triphasic oral contraceptive in private practice


, : Evaluation of a new triphasic oral contraceptive in private practice. Contraception 34(5): 435-442

We evaluated the clinical and metabolic effects of a new triphasic regimen developed in the continuing attempt to reduce the dose of estrogen and progesteron in oral contraceptives. A combination of ethinyl estradiol (EE) and levonorgestrel (LNg) was used (six tablets with 30 .mu.g EE + 50 .mu.g LNg, five tablets with 40 .mu.g EE + 75 .mu.g LNg, and 10 tablets with 30 .mu.g EE + 125 .mu.g LNg), also known as Triphasil (Wyeth). In a private practice, 409 subjects participated in 7,286 treatment cycles. Three pregnancies occurred, all due to subject failure. Menstrual regulation was excellent and the incidence of side effects extremely low. Withdrawals from the study for possibly drug-related medical reasons totaled 9.0% through 56 cycles of treatment. Metabolic changes also were evaluated in 14 of these women over a 6-month period. The only statistically significant increased in carbohydrate values occurred at 6 months. The mean glucose level at 30 minutes of the oral glucose tolerance test was above the baseline mean value, but serum insulin levels showed no statistically significant deviation. Lipid values presented are total lipids, total cholesterol, triglycerides, .alpha.-, .beta.-, and pre-.beta.-lipoproteins, and high density and low density lipoprotein cholesterol. There was no statistically significant difference between the mean values at the baseline and those during treatment for any lipid variable. These results indicate that this triphasic oral contraceptives has a high degree of efficacy, a low incidence of side effects, excellent cycle control, and high subject compliance, and would seem to indicate a minimal influence on the metabolism of lipids and carbohydrates in the small number of subjects studied.

Accession: 005395451

PMID: 3102161

DOI: 10.1016/0010-7824(86)90053-3

Download PDF Full Text: Evaluation of a new triphasic oral contraceptive in private practice


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Gauthier, A.; Upmalis, D.; Dain, M.-Paule, 1992: Clinical evaluation of a new triphasic oral contraceptive: Norgestimate and ethynylestradiol. The safety and efficacy of the triphasic oral contraceptive agent containing norgestimate and ethinyl estradiol were evaluated in a 12-month study of 661 women. Excellent contraceptive efficacy was achieved, with two pregnancies ascribed to produc...

Casper, R.F.; Powell, A.M., 1991: Evaluation and therapy of breakthrough bleeding in women using a triphasic oral contraceptive. This study was designed to investigate the incidence and pattern of breakthrough bleeding (BTB) in 1,259 women who were prescribed for the first time a triphasic oral contraceptive (OC, 7-7-7) and to evaluate a hypothesis of management for BTB per...

Gauthier, A.; Upmalis, D.; Dain, M.P., 1992: Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. The safety and efficacy of the triphasic oral contraceptive (OC) containing norgestimate and ethinyl estradiol were evaluated in a 12-month study of 661 women. Excellent contraceptive efficacy was achieved, with 2 pregnancies ascribed to product f...

London, R.S.; Chapdelaine, A.; Upmalis, D.; Olson, W.; Smith, J., 1992: Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Norgestimate (NGM), a derivative of 19-nortestosterone with very specific affinity for the progesterone receptor, has been used in combination with ethinyl estradiol (EE) in low doses in both monophasic and triphasic oral contraceptives (OCs). An...

Woods E.R.; Grace E.; Havens K.K.; Merola J.J.; Emans S.J., 1992: Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. OBJECTIVE: This study was undertaken to assess the impact of two low-dose oral contraceptive pills on compliance and side effects in adolescent patients. STUDY DESIGN: The use of a levonorgestrel-containing triphasic pill (N = 114) was compared wi...

Kalbag, J.; Elder, C.; Scott, G.; Wang, Y.; Milosavljev, S.; Leese, P.; Caldwell, J.; Rordorf, C., 2004: Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. This study evaluated the effect of lumiracoxib on the pharmacokinetics and pharmacodynamics of ethinyl estradiol (EE) and levonorgestrel (LN) in Triphasil(R)-28 (a triphasic oral contraceptive). Females stabilized on Triphasil(R)-28 continued on T...

Piérard-Franchimont, C.; Gaspard, U.; Lacante, P.; Rhoa, M.; Slachmuylders, P.; Piérard, G.E., 2001: A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. To investigate the effect of a triphasic low-dose oral contraceptive pill containing gestodene on acne severity and hormone levels in young women over 13 menstrual cycles. A total of 33 subjects aged 16-25 years with moderate facial acne were enro...

Krueger, H.G.; Sanders, J.H., 1964: Norethindrone And Mestranol. Experience In Private Practice With A New Low-Dosage Oral Contraceptive. Ohio State Medical Journal 60: 548-550

Woutersz, T.B.; Butler, A.J.; Cohen, M.; Korba, V.D.; Canavan, R.C., 1987: A low-dose triphasic oral contraceptive. Controlled clinical investigations of a three-phase, low-dose oral contraceptive combination of levonorgestrel and ethinyl estradiol were conducted at 17 sites in the United States and 60 sites in the United Kingdom. A day 1 start in cycle one wit...

Pasquale, S.A., 1984: Rationale for a triphasic oral contraceptive. Clinical observation on the use of various oral contraceptive (OC) formulations and the normal hormonal cycle formed the basis for development of Ortho-Novum 7/7/7, a triphasic with a constant low dose of 35 mcg ethinyl estradiol for all 21 tablet...